Biochemistry and Molecular Biology
Penn State Science
You are here: Home About News Articles 2018 News Articles CURE Sanfillipo Announces Support of Autophagy Research

CURE Sanfillipo Announces Support of Autophagy Research

Main Content

August 28, 2018 - Cure Sanfilippo Foundation awarded funding support to Dr. Scott Selleck and the Pennsylvania State University (Penn State) to study the cellular process of autophagy as a central mechanism in MPS (mucopolysaccharidosis) disease progression in the central nervous system.

Dr. Selleck lab members

Dr. Selleck’s prior research specialized in neurodevelopment, proteoglycan genetics and biochemistry. His neurodevelopment work has investigated the genetic basis of autism spectrum disorder and gene-environment interactions. Preliminary work with the Multiple Sulfatase Deficiency (MSD) fruit fly model has shown autophagy suppression, prompting Dr. Selleck to translate that finding to the mouse model in another MPS disorder.

Autophagy is a process by which cells engulf and dispose of misfolded proteins and damaged mitochondria that occur during normal metabolism and even more so in disease states. Research has shown that in Sanfilippo syndrome, as well as many other neurodegenerative diseases, there is an impairment in the body’s ability to carry out the autophagy process. This causes other parts of the cell to function poorly and eventually leads to cell death.

“Our focus is to provide both the scientific underpinnings and means of rescuing neuronal loss in children with MPS disorders. We hope these findings and methods will also translate to other neurodegenerative diseases.” Scott Selleck, MD, PhD

This project will specifically look at the effects of activating autophagy in the brains of MPSIIIA mice, either directly, or by inhibiting Tor, a master regulator and suppressor of autophagy. Since mTOR is a universal pathway that is not disease specific, findings here would be translatable across MPS conditions and neurodegenerative disorders. This pathway will be studied both through genetic modification and the use of an FDA approved class of
drugs known to block mTOR activity. This drug is currently used to treat children with tuberous sclerosis complex and has been shown to reduce seizure frequency and severity.

“Dr. Selleck’s work will provide further insight into a possible way to impact the neurodegenerative process in Sanfilippo syndrome, beyond replacing the primary enzyme deficiency. Developing complementary strategies, such as this, to improve the life of children with this devastating disease is a critical need.”, said Dr. Cara O’Neill, Scientific Director at Cure Sanfilippo Foundation.